Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Mikolaj Milewski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc. 126 East Lincoln Avenue, P.O. Box 2000 Rahway New Jersey 07065 United States. Hauptthemen laut MEDLINE: Biological Availability, Antibodies, Monoclonal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
Subcutaneous delivery of monoclonal antibody therapeutics is often preferred to intravenous delivery due to better patient compliance and overall lower cost to the healthcare system. However, the systemic absorption of biologics dosed subcutaneously is often incomplete. The aim of this work was to describe a human bioavailability prediction method for monoclonal antibodies delivered subcutaneously that utilizes intravenous pharmacokinetic parameters as input. A two-compartment pharmacokinetic model featuring a parallel-competitive absorption pathway and a presystemic metabolism pathway was employed. A training data set comprised 19 monoclonal antibodies (geometric mean bioavailability of 68%), with previously reported human pharmacokinetic parameters, while a validation set included data compiled from 5 commercial drug products (geometric mean bioavailability of 69%). A single fitted absorption rate constant, paired with compound-specific estimates of presystemic metabolism rate proportional to compound-specific systemic clearance parameters, resulted in calculations of human subcutaneous bioavailability closely mimicking clinical data in the training data set with a root-mean-square error of 5.5%. Application of the same approach to the validation data set resulted in predictions characterized by 12.6% root-mean-square error. Factors that may have impacted the prediction accuracy include a limited number of validation data set compounds and an uncertainty in the absorption rate, which were subsequently discussed. The predictive method described herein provides an initial estimate of the subcutaneous bioavailability based exclusively on pharmacokinetic parameters available from intravenous dosing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc. 126 East Lincoln Avenue, P.O. Box 2000 Rahway New Jersey 07065 United States.
ORCID-Profile: Mikolaj Milewski, Yash Kapoor
Förderung
- Merck
Zitieren
APA
Milewski, M., Murashov, M., Kapoor, Y., Zhang, J., Zhu, W., Cueto, M. A., & Buist, N. (2024). Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00132
Vancouver
Milewski M, Murashov M, Kapoor Y, Zhang J, Zhu W, Cueto MA, et al. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00132
BibTeX
@article{Milewski2024,
author = {Milewski, Mikolaj and Murashov, Mikhail and Kapoor, Yash and Zhang, Jingtao and Zhu, Wei and Cueto, Maria A and Buist, Nicole},
title = {Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00132}
}
EUVIMED